CHO, HYUK JUN,曹赫俊,YOON, YOUNG MIN,尹英民,KIM, KYEONG SOO,金京洙,PARK, JAE HYUN,朴宰贤,朴宰賢,WOO, JONG SOO,禹锺守,禹鍾守
申请号：
TW104132119
公开号：
TW201618759A
申请日:
2015.09.30
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
A dry powder for an inhalation formulation and an inhalation formulation including the dry powder. The dry powder includes: at least two combined active ingredients selected from the group consisting of salmeterol or a pharmaceutically acceptable salt thereof, tiotropium or a pharmaceutically acceptable salt thereof, and fluticasone or a pharmaceutically acceptable salt thereof； and a diluent, wherein the diluent includes about 0.1wt% to about 50wt% of micronized powder having an average particle diameter (X50) of about 30 μm or less based on a total weight of the diluent so that the stability of at least one of the active ingredients is higher than that of a dry powder having a micronized powder content exceeding 50wt%.用於吸入型調配物之一乾粉末及包括此乾粉末之一吸入型調配物。此乾粉末包括：選自由沙美特羅(salmeterol)或其一藥學上可接受鹽、替托比銨(tiotropium)或其一藥學上可接受鹽，及氟替皮質醇(fluticasone)或其一藥學上可接受鹽所組成組群之至少二組合型活性成分；及一稀釋劑，其中，以此稀釋劑之總重量為基準，此稀釋劑包括約0.1重量%至約50重量%之具有約30μm或更少之平均顆粒直徑(X50)之經微米化之粉末，使得該等活性成分之至少一者的穩定性係高於具有超過50重量%之經微米化之粉末含量一乾粉末的穩定性。
